• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crispr Therapeutics Ag (NQ: CRSP )

    56.98 -0.94 (-1.62%)
    Streaming Delayed Price Updated: 1:27 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Crispr Therapeutics Ag

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    27 28 Next >
    Cathie Wood's Ark Invest Sells $8.04M Worth of DraftKings Shares
    Via Benzinga
    Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
    FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the... 
    Via Benzinga
    Exposures Product Safety
    Cathie Wood's Ark Invest Liquidates $15.8M Worth Of ProShares Bitcoin Strategy ETF Units
    On Tuesday, Cathie Wood-led Ark Invest made a significant move by selling $15.84 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO) units. 
    Via Benzinga
    Topics ETFs
    Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
    Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. 
    Via Investor's Business Daily
    These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge
    These risky stocks can deliver big returns for investors. 
    Via The Motley Fool
    Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
    Via Benzinga
    Here's Why CRISPR Therapeutics Stock Rose 54% Last Year
    Key regulatory developments sent this biotech stock higher. 
    Via The Motley Fool
    5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
    These five biotech companies could have a lot of room to run. 
    Via The Motley Fool
    Down 88%, Could Editas Medicine Be a Good Investment Now?
    The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. 
    Via The Motley Fool
    What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
    An acquisition could be both a blessing and a curse for long-term investors. 
    Via The Motley Fool
    7 Healthcare Stocks Taking Medicine to the Next Level
    With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
    Via InvestorPlace
    My 3 Highest-Conviction Growth Stocks to Buy in 2024
    Simply put, these stocks inspire confidence. 
    Via The Motley Fool
    My 5 Top Growth Stocks to Buy Hand Over Fist for 2024
    2024 could be a year of growth. 
    Via The Motley Fool
    Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week
    These companies could stand out thanks to game-changing technology. 
    Via The Motley Fool
    2 Red Flags for Bluebird Bio Stock
    The biotech's struggles may continue. 
    Via The Motley Fool
    3 Cathie Wood Stocks to Start Off Your New Year Right
    The following stocks could deliver big gains over time. 
    Via The Motley Fool
    The Ultimate Growth Stock to Buy With $1,000 Right Now
    The stock, trading for about $60, has plenty of room to run. 
    Via The Motley Fool
    5 Innovative Stocks That Could Score a Win for Your Portfolio in 2024
    You'll find exciting innovators across industries. 
    Via The Motley Fool
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
    Via Investor's Business Daily
    2 Biotech Stocks With Huge Catalysts in 2024
    Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
    Via The Motley Fool
    Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
    Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
    Via InvestorPlace
    Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
    CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
    Via The Motley Fool
    3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
    Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
    Via InvestorPlace
    Better Risky Investment: Bluebird Bio vs. Shiba Inu
    Few investors dare to tread where the ice is known to be very thin. 
    Via The Motley Fool
    3 Biotech Stocks Set for Breakthroughs in 2024
    With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
    Via InvestorPlace
    3 No-Brainer Growth Stocks to Buy for Less Than $100
    These businesses have promising futures and make for great investment options today. 
    Via The Motley Fool
    1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
    Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
    Via The Motley Fool
    2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
    Curing rare inherited illnesses could be a lucrative business model. 
    Via The Motley Fool
    2023 in Review: Nvidia, Interest Rates, Taylor Swift
    And a little bit of real estate insight. 
    Via The Motley Fool
    3 Stocks That Could Be Monster Winners in 2024
    Don't be surprised if these three stocks take off in the new year. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    27 28 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.